Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Nearly three decades ago, Dr. Peter Mugyenyi, a leading authority on the treatment of HIV/AIDS in Africa, posed a question that has lost none of its sting today: “Where are the drugs? The drugs are where the disease is not. And where is the disease? The disease is where the drugs are not.” No matter how effective, a medicine cannot reach patients until it is authorized by their country’s medicines regulator.
This is a crosspost of the full text of Can Africa regulate as a continent?from In Development, made for the EA Forum's In Development Highlight Week. If you enjoy the article, you can subscribe to In Development's substack here. The problem of regulatory delay The drug tenofovir disoproxil fumarate, a cornerstone of HIV treatment, was approved by the United States Food and Drug Administration in 2001. Its better safety profile quickly made it a standard treatment in the US and Europe.
This post is also available on the In Development website. The drug tenofovir disoproxil fumarate, a cornerstone of HIV treatment, was approved by the United States Food and Drug Administration in 2001. Its better safety profile quickly made it a standard treatment in the US and Europe.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
